FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386142904> ?p ?o ?g. }

• W4386142904 endingPage "e96103aa" @default.
• W4386142904 startingPage "e96103aa" @default.
• W4386142904 abstract "Background: Treatment outcomes for patients with chronic lymphocytic leukemia (CLL) have improved with the introduction of targeted agents. Prior research has shown that Black patients (pts) with CLL had shorter survival compared to White non-Hispanic pts. Here, we assess for the first time if there are disparities for Black pts in treatment options and outcomes in real-world clinical practice in the contemporary era of targeted agents. Aims: To assess demographic, clinical, and treatment characteristics and outcomes in first-line (1L) therapy for Black and White pts. Methods: From the 19 US-based centers of the CLL Collaborative Study of Real-World Evidence (CORE), a retrospective, international, observational study, adult Black and White non-Hispanic pts with CLL were selected if they initiated 1L therapy on/after 01/01/2014 outside of clinical trials and classified into 2 mutually exclusive cohorts. Cohorts were balanced using stabilized inverse probability treatment weighting (S-IPTW) on sex, age at 1L, year of 1L, time from CLL diagnosis to 1L, insurance type, ECOG, Rai stage, IGHV, del(17p)/TP53 mutations, and number of comorbidities. Balance was assessed using standardized mean difference and variance ratio. Demographic, clinical, and treatment characteristics were assessed at 1L start. 1L treatment outcome was progression-free survival (PFS). Results: Of the 979 pts included, 110 pts (11.2%) were Black, 336 (34.3%) female (Black: 40[36.4%], White: 296[34.1%]), median age at diagnosis was 63.3 years (Black: 63.3, White: 63.3) with a median follow-up of 22.4 months (mos; Black: 20.2, White: 23.2). Before weighting, Black pts were younger at 1L start (median age: 64.4 vs 66.6), had a higher proportion of pts on Medicaid/no insurance (10.9% vs 3.3%), lacked Rx benefits (10% vs 3.8%), and started 1L sooner after CLL diagnosis (2.8 vs 20.9 mos) relative to White pts. Black pts also had a higher proportion with unmutated IGHV (75.8% vs 62.9%), ATM (16.2% vs 9.3%), and NOTCH1 (8.1% vs 4.2%) mutations, higher comorbidity burden (median number of comorbidities: 2 vs 1), and a lower proportion of pts with 17del/TP53 mutations (13.6% vs 17.9%) relative to White pts. Similarly, a higher proportion of Black pts had only 1 line of treatment (65.5% vs 62.1%), never received a targeted agent during follow-up (30.0% vs 23.2%), and were treated with CT/CIT in 1L (48.2% vs 34.4%); between 2014-2016 (63.3% vs 48.9%) relative to 2017-2022 (37.9% vs 23.9%). Median 1L treatment duration was ~14 mos in both cohorts. Median PFS was 14.8 mos shorter for Black than White patients (Figure 1). After weighting, the cohorts were well-balanced in their characteristics, yet the median PFS remained shorter for Black than White pts (10.4 mos shorter); 11.6 mos shorter in 2014-2016 though not in 2017-2022 (1.8 mos longer; Figure 1). Summary/Conclusion: Racial disparities were observed in clinical characteristics, comorbidity burden, and type of therapy at the time of treatment initiation for 1L CLL, resulting in a large disadvantage in the median PFS for Black pts in the years immediately following the advent of targeted agents. However, after weighting, this difference in the median PFS was attenuated relative to White pts. These data suggest that access to adequate care with more effective targeted treatments may help reduce racial disparities for pts in real-world settings, as well as reducing their comorbidity burden. Our study highlights the importance of inclusion of pts from different backgrounds in clinical trials to study clinical outcomes prospectively.Keywords: Chronic lymphocytic leukemia" @default.
• W4386142904 created "2023-08-25" @default.
• W4386142904 creator A5001204133 @default.
• W4386142904 creator A5003761856 @default.
• W4386142904 creator A5006235077 @default.
• W4386142904 creator A5007113253 @default.
• W4386142904 creator A5008419917 @default.
• W4386142904 creator A5009147018 @default.
• W4386142904 creator A5010100538 @default.
• W4386142904 creator A5010673295 @default.
• W4386142904 creator A5016570475 @default.
• W4386142904 creator A5017578509 @default.
• W4386142904 creator A5019997972 @default.
• W4386142904 creator A5041446999 @default.
• W4386142904 creator A5042723532 @default.
• W4386142904 creator A5051296565 @default.
• W4386142904 creator A5053298824 @default.
• W4386142904 creator A5055100327 @default.
• W4386142904 creator A5059264128 @default.
• W4386142904 creator A5059291247 @default.
• W4386142904 creator A5063755644 @default.
• W4386142904 creator A5067536059 @default.
• W4386142904 creator A5067905920 @default.
• W4386142904 creator A5069611687 @default.
• W4386142904 creator A5070882299 @default.
• W4386142904 creator A5074766331 @default.
• W4386142904 creator A5074839524 @default.
• W4386142904 creator A5079426839 @default.
• W4386142904 creator A5082526059 @default.
• W4386142904 creator A5088826331 @default.
• W4386142904 creator A5089449036 @default.
• W4386142904 date "2023-08-01" @default.
• W4386142904 modified "2023-10-14" @default.
• W4386142904 title "P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL" @default.
• W4386142904 doi "https://doi.org/10.1097/01.hs9.0000969492.96103.aa" @default.
• W4386142904 hasPublicationYear "2023" @default.
• W4386142904 type Work @default.
• W4386142904 citedByCount "0" @default.
• W4386142904 crossrefType "journal-article" @default.
• W4386142904 hasAuthorship W4386142904A5001204133 @default.
• W4386142904 hasAuthorship W4386142904A5003761856 @default.
• W4386142904 hasAuthorship W4386142904A5006235077 @default.
• W4386142904 hasAuthorship W4386142904A5007113253 @default.
• W4386142904 hasAuthorship W4386142904A5008419917 @default.
• W4386142904 hasAuthorship W4386142904A5009147018 @default.
• W4386142904 hasAuthorship W4386142904A5010100538 @default.
• W4386142904 hasAuthorship W4386142904A5010673295 @default.
• W4386142904 hasAuthorship W4386142904A5016570475 @default.
• W4386142904 hasAuthorship W4386142904A5017578509 @default.
• W4386142904 hasAuthorship W4386142904A5019997972 @default.
• W4386142904 hasAuthorship W4386142904A5041446999 @default.
• W4386142904 hasAuthorship W4386142904A5042723532 @default.
• W4386142904 hasAuthorship W4386142904A5051296565 @default.
• W4386142904 hasAuthorship W4386142904A5053298824 @default.
• W4386142904 hasAuthorship W4386142904A5055100327 @default.
• W4386142904 hasAuthorship W4386142904A5059264128 @default.
• W4386142904 hasAuthorship W4386142904A5059291247 @default.
• W4386142904 hasAuthorship W4386142904A5063755644 @default.
• W4386142904 hasAuthorship W4386142904A5067536059 @default.
• W4386142904 hasAuthorship W4386142904A5067905920 @default.
• W4386142904 hasAuthorship W4386142904A5069611687 @default.
• W4386142904 hasAuthorship W4386142904A5070882299 @default.
• W4386142904 hasAuthorship W4386142904A5074766331 @default.
• W4386142904 hasAuthorship W4386142904A5074839524 @default.
• W4386142904 hasAuthorship W4386142904A5079426839 @default.
• W4386142904 hasAuthorship W4386142904A5082526059 @default.
• W4386142904 hasAuthorship W4386142904A5088826331 @default.
• W4386142904 hasAuthorship W4386142904A5089449036 @default.
• W4386142904 hasBestOaLocation W43861429041 @default.
• W4386142904 hasConcept C126322002 @default.
• W4386142904 hasConcept C143998085 @default.
• W4386142904 hasConcept C144024400 @default.
• W4386142904 hasConcept C149923435 @default.
• W4386142904 hasConcept C187212893 @default.
• W4386142904 hasConcept C23131810 @default.
• W4386142904 hasConcept C2777609679 @default.
• W4386142904 hasConcept C2777938653 @default.
• W4386142904 hasConcept C2778461978 @default.
• W4386142904 hasConcept C535046627 @default.
• W4386142904 hasConcept C71924100 @default.
• W4386142904 hasConceptScore W4386142904C126322002 @default.
• W4386142904 hasConceptScore W4386142904C143998085 @default.
• W4386142904 hasConceptScore W4386142904C144024400 @default.
• W4386142904 hasConceptScore W4386142904C149923435 @default.
• W4386142904 hasConceptScore W4386142904C187212893 @default.
• W4386142904 hasConceptScore W4386142904C23131810 @default.
• W4386142904 hasConceptScore W4386142904C2777609679 @default.
• W4386142904 hasConceptScore W4386142904C2777938653 @default.
• W4386142904 hasConceptScore W4386142904C2778461978 @default.
• W4386142904 hasConceptScore W4386142904C535046627 @default.
• W4386142904 hasConceptScore W4386142904C71924100 @default.
• W4386142904 hasIssue "S3" @default.
• W4386142904 hasLocation W43861429041 @default.
• W4386142904 hasOpenAccess W4386142904 @default.
• W4386142904 hasPrimaryLocation W43861429041 @default.
• W4386142904 hasRelatedWork W1876001658 @default.
• W4386142904 hasRelatedWork W1965035229 @default.
• W4386142904 hasRelatedWork W2558062410 @default.

• next